Montreal’s NEOMED Institute needs more space to accommodate growing demand for its facilities and services. Discussions are underway with an unnamed third party equity investor to finance the expansion of its Laval facility with a decision expected within weeks. NEOMED’s growth proves it is possible to come up with a business model that can retain top talent in a region when big pharma employers decide to move out.
Organizations: | AstraZeneca, BlueRock Therapeutics, MerckFrosst for Centre Therapeutic Research, NEOMED, Science Translational Medicine magazine, and Technoparc Montreal |
People: | Donald Olds |
Topics: | Quebec life sciences strategy |